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Obesity rates are rapidly increasing worldwide andfacilitate the development of many related diseasestates, such as cardiovascular
disease, the metabolic syndrome, type 2 diabetes mellitus, and various types of cancer. Variation in metabolically important
genes can have a great impact on a population’s susceptibility to becoming obese and/or developing related complications. The
adipokines adiponectin and leptin, as well as the leptin receptor, are major players in the regulation of body energy homeostasis
and fat storage. This paper summarizes the ﬁndings of single nucleotide polymorphisms in these three genes and their eﬀect on
obesity and metabolic disease risk. Additionally, studies of gene-nutrient interactions involving adiponectin, leptin, and the leptin
receptor are highlighted to emphasize the critical role of diet in susceptible populations.
1.Introduction
Obesity is the result of an imbalance in energy homeostasis
andischaracterizedbyincreasedadiposetissuemass,chronic
low-grade inﬂammation, insulin resistance, and endothelial
dysfunction. Obesity is a major risk factor for type 2 diabetes
mellitus (T2DM), cardiovascular disease (CVD), and several
types of cancer [1–3], and lies at the core of a cluster of
metabolic abnormalities deﬁned as the metabolic syndrome,
which includes insulin resistance and hyperinsulinemia,
hypertension, impaired glucose tolerance, and T2DM [4].
AccordingtotheNationalHealthandNutritionExamination
Survey (NHANES), 33.8% of American adults are obese
(BMI ≥ 30) and 68.0% are considered overweight or obese
(BMI ≥ 25) [5]. Dietary choices (and overeating) in com-
bination with low physical activity are typically attributed
as the root cause of the rapid spread of the obesity epide-
mic in the modern world [6], but genetic factors are a
strong determinant of individual susceptibility to obesity.
The growing prevalence of obesity and obesity-related
pathologieshas spurred thesearch for greaterinsight intothe
mechanisms that contribute to the development of obesity
and its complications.
Adipose tissue plays multiple important roles in body
weight regulation and energy homeostasis. Adipose func-
tions as an energy storage organ, storing fat primarily
in the form of triglycerides and releasing free fatty acids
as the body’s energy demands change. Adipose tissue is
also an active endocrine organ, secreting many cytokines,
chemokines, and hormone-like factors. These molecules,
which are produced and secreted primarily by adipocytes,
are known as adipokines [7]. Adipokines constitute a diverse
group of bioactive peptides with many and varied roles,
including mediation of glucose and lipid metabolism, blood
pressure regulation, and modulation of inﬂammation and
immune function [8]. While over 100 adipokines have
been identiﬁed [9], the speciﬁc functions of many of2 Journal of Obesity
these molecules are poorly understood. Regardless, it has
been clearly established that in obesity, adipocytes undergo
hypertrophy and become dysfunctional [10, 11]. As a result,
the adipokine proﬁle they express and secrete is altered,
leading to a proinﬂammatory environment both locally and
systemically, and contributing to the pathological eﬀects of
obesity.
Sincemany criticalmetabolic functions are inﬂuencedby
adipokines, genetic variations that aﬀect their eﬃcacy may
contribute to various pathophysiological states. Forinstance,
genetic variation in adipokine genes has been shown to
modulate circulating adipokine levels and thus could pre-
dispose carriers of single nucleotide polymorphisms (SNPs)
to developing obesity or other metabolic illnesses in which
adipokines play a prominent role, or alternatively, provide
them some protection against disease. Studying the impact
of such gene polymorphisms in human populations can
provide insight into the roles speciﬁc adipokines play in
obesity and related pathologies. This paper will discuss the
association of SNPsin the protein-coding genesfor two well-
studied adipokines, adiponectin and leptin, as well as the
leptin receptor, in the context of obesity-related metabolic
disease. In addition, due to the profound eﬀe c tt h a td i e tc a n
have on weight gain and regulation, the recent literature on
nutrient-gene interaction studies involving adipokines and
dietary factors will be highlighted.
2.Methods
Articles for this review were identiﬁed using the PubMed/
Medline databases. Search terms included “single gene poly-
morphism”, “genevariant”,“adiponectin”, “AdipoQ”,“leptin”,
“leptin receptor”, and “obesity” or “metabolic disease”. An
emphasis was placed on studies published in the last decade,
but the search was not limited to a speciﬁc time interval.
The articles were chosen by scanning the abstract to ensure
relevancy. Only studiesin human populationsand in English
were included.
3.Adiponectin
Adiponectin is an important anti-inﬂammatory and insulin-
sensitizing hormone and promotes lipid oxidation in tissues
such as skeletal muscle and liver [12, 13]. Adiponectin
also has direct antiatherosclerotic properties, as it strongly
inhibitsexpression ofadhesionmoleculesandgrowthfactors
[14]. Adiponectin serum levels are inversely correlated with
body fat percentage in obese subjects, as well as in those
aﬄicted with T2DM or coronary heart disease [15, 16].
Due to the protective nature of adiponectin in many types
of cardiovascular and metabolic disease states, low serum
levels of this adipokine are thought to contribute to the
pathogenesis of these conditions. Several excellent reviews
on the various roles of adiponectin are available [17–20].
The adiponectin gene AdipoQ has been identiﬁed as a
susceptibility locus for the metabolic syndrome, T2DM and
CVD [21, 22]. AdipoQ is located on chromosome 3q27. The
gene is 15.8 kb long and contains three exons.
3.1. Adiponectin Levels and Obesity-Related Metabolic Disease
Parameters. It is estimated that a 30–70% variation in
normal circulating adiponectin levels can be attributed to
genetic factors [23–29]. A total of 42 SNPs in AdipoQ
and its regulatory region with a minor allele frequency
of >1.5% have been identiﬁed [30]. Table 1 lists AdipoQ
SNPs studied in the last decade and their relation (if any)
to adiponectin levels and other obesity-related metabolic
disease parameters. Since changes in adiponectin due to
genetic variation are of particular interest in this paper, the
table highlights the percent change in adiponectin levels
in those studies that reported this parameter. Four SNPs
(−11391 G > A, −11377 C > G, +45 T > G and +276 G >
T) were analyzed with far greater frequency than any others
and will be the focus of the following discussion.
The majority of studies analyzing the SNP −11391 G
> A found a favourable increase in circulating adiponectin
levels in those subjects carrying the A allele. A recent meta-
analysis determined that SNP −11391 G>A was associated
with adiponectin levels according to a dominant model with
A allele carriers (GA and AA genotypes) having higher
adiponectin levels compared with GG carriers [29]. An
in vitro study supports these data, reporting a biological
function of this SNP with the A allele enhancing AdipoQ
promoter activity [31] .D e s p i t et h ep r e v a l e n c eo ft h eh i g h
adiponectin ﬁnding, most studies did not report any associ-
ation with improved health in their subjects. Only one study,
an analysis of a Caucasian population from Italy, showed
a decrease in obesity-related risk factors (BMI, weight,
and waist and hip circumference) [32]. Three studies had
conﬂictingﬁndings. InastudyofEuropeanchildrencarrying
the A allele, adiponectin levels were found to be higher,
similar to the situation in adults; however, the SNP showed
an obesity-mediated detrimental association with fasting
serum insulin and HOMA-IR [33]. A second study involving
obese and morbidly obese French Caucasians found the SNP
to be associated with lower adiponectin levels, but similarly
accompanied by lower insulin sensitivity and a higher risk of
T2DM [32]. In a third study, there was also an association
between the GA genotype and risk of hyperglycemia in
a population of French Caucasians [34]. While it is clear
that most carriers of the A allele have raised adiponectin
levels and could expect to be protected from metabolic
disease, in certain populations the increase in adiponectin
observed in GA and AA carriers appears to be too small to
impart any appreciable metabolic advantage, where it fails to
counterbalance the metabolic damages of obesity. In fact, it
may contribute to the increased risk for childhood obesity
and related insulin resistance.
The ﬁndings on the −11377 G > C SNP are inconsistent,
butthe general trend links the G allele to various detrimental
conditions, including lower adiponectin levels [23, 42, 43,
45, 48], risk for developing hypertension [43], and, in some
cases, risk fordevelopingcolorectalcancer[46].Ontheother
hand, the presence of the C allele has also been associated
with higher BMI and obesity risk [31, 36], increased fasting
glucose levels and T2DM risk [35, 42]. For example, a
study that investigated genetic variations in adiponectin
in individuals with metabolic syndrome found that SNPJournal of Obesity 3
Table 1: SNPs in the adiponectin gene AdipoQ.
SNP ID Position Parameter association Population
Adiponectin
level
(% change)
P value Reference
rs860291 −12823 No associationwith T2DM,
BMI, or insulin sensitivity Pima Indians [24]
rs16861194
−11426
G > A
SNP associated with increased
risk for gaining weight in
diabetics
Chinese (T2DM) [35]
SNP associated with fasting
plasma glucose in T2DM
patients and in those with
impaired glucose tolerance
Swedish Caucasians
(T2DM/ impaired
glucose tolerance/
nondiabetic)
[36]
G allele moderately associated
with T2DM French Caucasians [37]
rs17300539
−1391
G > A
A allele associated with higher
adn levels, higher BMI, and
obesity
Children of
European origin 13.39 6.00E-08 [33]
A allele carriers have lower
weight, waist and hip
circumferences and BMI
[32]
GA carriers had increased risk
for becoming
hyperglycaemic/diabetic
French Caucasians [34]
A allele associated with higher
adn levels French Caucasians .0001 [23]
A allele associated with higher
adn levels
Hispanic Americans
and African
Americans
18.89 .0001 [27]
A allele associated with higher
adn levels Caucasians [38]
A allele associated with higher
adn levels Caucasian women 36.93 .0006 [39]
A allele associated with higher
adn levels in obese children
French Caucasians
(obese/lean)
.005 [31]
A allele associated with higher
adn
Caucasian and
African American
adolescents
29.41 .002 [40]
A allele associated with higher
adn levels Caucasians 19.05 .0005 [41]
A associated with lower adn
levels, lower insulin sensitivity,
and higher risk of T2DM in
obese subjects
French Caucasians
(lean/obese) 32.01 .0003 [42]
rs266729
−11377
G > C
C allele associated with higher
fasting plasma glucose levels
in diabetics
Chinese (T2DM) [35]
C allele associated with severe
obesity
French Caucasians
(obese/lean)
[31]
G allele associated with lower
adn levels, higher risk of
hypertension
Chinese
(hypertensive)
.0037 [43]
SNP associated with increase
in plasma oxidative stress
markers
T2DM patients [44]4 Journal of Obesity
Table 1: Continued.
SNP ID Position Parameter association Population
Adiponectin
level
(% change)
P value Reference
G allele associated with lower
adn levels, lower insulin
sensitivity, and higher risk of
T2DM in obese subjects
French Caucasians
(lean/obese) 20.66 .008 [42]
G allele associated with
coronary stenoses and lower
adn levels
European men with
CVD 26.92 .003 [45]
SNP associated with increased
risk for colorectal cancer Czech patients [46]
No associationwith adn levels CaucasianItalians [32]
No associationwith colorectal
cancer risk UK [47]
GG and CG associated with
lower CRC risk
American CRC
patients
[48]
G associated with lower adn
levels French Caucasians .0003 [23]
CC and CG genotypes had
higher BMI than GG
Swedish Caucasians
(T2DM/ impaired
glucose tolerance/
nondiabetic)
[36]
−11365 SNP associated with lower
plasma adn levels 18.36 .007 [49]
No associationwith T2DM,
BMI, or insulin sensitivity Pima Indians [24]
−10677
C > T
SNP associated with lower adn
levels
Chinese
(hypertensive)
.0027 [43]
rs182052
−10068
G > A
A allele associated with lower
adn levels
Hypertensive
Chinese
.0001 [43]
A allele associated with waist
circumference
American Caucasian
young adults
[50]
G allele associated with higher
adn
Caucasian and
African American
adolescents
17.58 0.03 [40]
−10066
G > A
G allele associated with higher
adn Caucasian women 8.67 .01 [39]
rs16861209 −7734 C > A A allele associated with higher
adn Caucasian women 22.68 .004 [39]
rs822395 −4041 A > C No associationwith adn levels Caucasian Italians [32]
−4034 CC associated with CVD risk [49]
−3971 G > A
A allele associated with worse
glucose tolerance and insulin
sensitivity, but not adn levels
CaucasianCanadians
(nondiabetic)
[51]
rs2241766 +45 T > G GG and TG genotypes were at
higher risk for T2DM Obese Iranians [52]
Both TG and GG genotypes
were associated with
gestational T2DM, whereas
amonghealthy participants,
the TT genotype had higher
a d nl e v e l st h a no t h e rg r o u p s
Pregnant (<18
weeks) Malaysian
women
19.92 .05 [53]Journal of Obesity 5
Table 1: Continued.
SNP ID Position Parameter association Population
Adiponectin
level
(% change)
P value Reference
G allele associated with lower
fasting insulin levels and lower
HOMA-IR score
Nondiabetic Greek
women
[54]
G allele associated with higher
TG, HOMA, fasting blood
glucose, BMI and ALT, and
lower adn levels; T allele
associated with lower body
weight
Chinese
(NAFLD/metabolic
syndrome)
28.68 .008 [55]
GG associated with T2DM Japanese [56]
G allele associated with T2DM
(lower insulin sensitivity),
lower adn, higher blood
pressure, higher LDL and total
cholesterol levels
Chinese (T2DM) 15.47 .01 [57]
A allele associated with worse
glucose tolerance and insulin
sensitivity, but not adn levels
CaucasianCanadians
(nondiabetic)
[51]
G allele associated with BMI
and waistcircumference Hispanic Americans [58]
GG carriers had higher risk of
becoming
hyperglycaemic/diabetic,
associated with increase in
BMI and WHR over 3 years
French Caucasian [34]
No diﬀerence in risk for
T2DM or IR
Korean (diabetic/
nondiabetic)
[59]
T allele and TG genotype
associated with lower serum
adn, no associationwith IR
Caucasians 25.17 .0008 [60]
GT genotype associated with
impaired glucose tolerance Spanish [61]
G allele conferred higher risk
of developing T2DM than TT
genotype, particularly when
combined with SNP +276 T
allele
European/Canadian
subjects with
impaired glucose
tolerance
[62]
T allele associated with lower
BMI and HOMA-IR
Japanese
(nondiabetic)
[63]
In obese subjects, serum
cholesterol and waist
circumference were lower in
TG genotype than in TT
genotype
Swedish women
(obese/lean)
[64]
No associationwith adn levels CaucasianItalians [32]
No associationwith risk for
coronaryartery disease
CaucasianItalians
(T2DM)
[65]
No associationwith T2DM,
BMI, or insulin sensitivity Pima Indians [24]
G allele associated with
coronaryartery disease in
T2DM patients
European Caucasians [66]
G associated with higher adn
levels French Caucasians .01 [23]6 Journal of Obesity
Table 1: Continued.
SNP ID Position Parameter association Population
Adiponectin
level
(% change)
P value Reference
rs1501299 +276 G > T T allele associated with obesity African American
men
[67]
GG associated with T2DM,
higher insulin resistance, and
lower adn levels in subjects
withhigher BMI
Japanese 10.40 .01 [56]
T allele associated with higher
adn levels Caucasian women 4.46 .0031 [39]
T allele associated with central
obesity and hyperglycemia
Indigenous
Taiwanese
[68]
T allele associated with lower
adn levels, diastolic blood
pressure
Finnish men 33.58 .001 [69]
T allele associated with higher
fasting insulin levels and
higher HOMA-IR score,
possible associationwith body
fat
Greek women
(nondiabetic)
[54]
GG genotype associated with
lower adn levels, impaired
glucose tolerance
Spanish .015 [61]
SNP associated with higher
rate of insulin resistance,
higher n-6/n-3 LCPUFA ratio
in plasma phospholipids
Normolipidaemic
obese children
[70]
T allele associated with severe
obesity, but not adn
French Caucasians
(obese/lean)
[31]
TT genotype associated with
lower CVD risk in diabetic
patients, those without CVD
had higher adn levels
American men
(T2DM) 27.03 .0029 [71]
T allele is an important
determinant of CAD and
lower adn levels in patients
with early onset CAD (50
years of age or less)
Italian CAD patients [72]
T allele associated with higher
adn
Caucasian and
African American
adolescents
4.95, 5.81 .05,.03 [40]
G allele carriers had higher
TG, higher small dense LDL,
and smaller LDL particle size;
GG had lower adn, higher
HOMA-IR
Korean (nondiabetic) 18.90 .026 [73]
No associationwith adn levels
or hypertension
Japanese men
(hypertensive/
normotensive)
[74]
No diﬀerence in allele
frequencies between diabetic
and nondiabetic, no diﬀerence
in risk of T2DM or insulin
resistance
Korean (diabetic/
nondiabetic)
[59]
No associationwith T2DM,
BMI, or insulin sensitivity Pima Indians [24]
TT genotype associated with
lower risk of coronary artery
disease in T2DM patients
CaucasianItalians
(T2DM)
[65]Journal of Obesity 7
Table 1: Continued.
SNP ID Position Parameter association Population
Adiponectin
level
(% change)
P value Reference
TT genotype associated with
higher adn levels CaucasianItalians .032 [32]
G allele, GT genotype
associated with lower serum
adn, no associationwith
insulin resistance
Caucasians 13.70 .00005 [60]
T allele associated with lower
BMI and HOMA-IR
Japanese
(nondiabetic)
[63]
T associated with higher adn
levels French Caucasians .01 [23]
rs1063538 +3228 C > T T allele associated with higher
adn levels Caucasian women 24.97 .036 [39]
rs1063538 +3286 No associationwith T2DM,
BMI, or insulin sensitivity Pima Indians [24]
+10211 T > G
G allele associated with higher
diabetes risk, higher BMI, and
lower adn levels
Asian Indians .007 [75]
rs12495941 G > T T allele associated with lower
adn levels
Chinese
(hypertensive)
.0001 [43]
rs3774261 A > G G allele associated with IR African Americans [76]
rs1656943
(rs822387) T > C C allele associated with higher
adn levels
Hispanic Americans
and African
Americans
12.62 .003 [27]
−11377 G > C was a determinant of HOMA-IR, where
CC homozygotes had signiﬁcantly lower HOMA-IR scores
[77]. There is evidence that the presence of the minor G
allele decreases the aﬃnity of the transcription factor Sp1
to its binding site within the AdipoQ promoter [78], and
a recent study showed that this allele had altered DNA-
binding activity, leading to lowerbasal and inducibleAdipoQ
promoter activity in mouse 3T3-L1 adipocytes [79]. The
mechanism by which the C allele might contribute to disease
remains unclear.
The silent +45 T > G SNP is strongly associated with
detrimental health eﬀects including lower adiponectin levels
[55, 57], higher BMI and lower insulin sensitivity [34,
55], higher risk for developing hyperglycemia and T2DM
[34, 52, 53, 56, 57, 62], and higher levels of blood lipids
(triglycerides, LDL cholesterol, and total cholesterol) [55,
57]. In contrast, the T allele generally appeared to aﬀord
the carrier some protection, being associated with higher
adiponectin levels [53] and lower body weight [55, 63]. A
few studiesobtained resultsthatdiﬀered,and some found no
signiﬁcant associations with these parameters atall; however,
theoveralltrendsremainedapparentevenacrosssuchdiverse
populations as Iranians, Japanese, and European Caucasians
[34, 52, 56]. The mechanisms by which these genetic varia-
tionsexerteﬀectsonadiponectinlevelsandmetabolicdisease
parameters have not been fully elucidated. Yang et al. [80]
showed that the silent +45 T > G mutation may alter RNA
splicing or stability, suggesting an allele-speciﬁc diﬀerential
expression of adiponectin. It is thus possible that SNPs with
no apparent biological signiﬁcance may have an eﬀect on
gene expression, although in this case it is likely that SNP
+45 is in linkage disequilibrium with some other functional
genetic alterations, resulting in the diﬀerence in mRNA
expression ofitstwoalleles. Otherresearch hasindicatedthat
the +45 T > G SNP is in linkage disequilibrium with the
+276 G > T SNP and that the haplotype deﬁned by the two
together is strongly associated with many components of the
metabolic syndrome [61, 62, 81].
The G allele of the +276 G > T SNP is primarily
associated withlowerinsulin sensitivityandincreased T2DM
risk, lower adiponectin levels, and increased blood lipids.
Conversely, many carriers of the T allele have higher
adiponectin levels and a lower BMI. Two notable exceptions
to thistrend are the studiesauthoredby Beebe-Dimmeret al.
[67]andBouatia-Naji etal. [31],in which thepresence ofthe
T allele corresponded with severe obesity. The ﬁrst of these
occurred in African American men, and so the conﬂicting
results may be attributed to the racial composition of the
populations studied. The second was a study of lean and
obese French Caucasians. The authors suggest that while
the higher adiponectin levels seen in the obese T allele
carriers may protect them against insulin resistance and
T2DM, hyperadiponectinemia may actually predispose these
patients to weight gain due to the insulin-sensitizing eﬀects
of adiponectin, which could promote lipid uptake and
storage [31, 82]. This mechanism may also explain why8 Journal of Obesity
some populations have higher adiponectin levels despite
being in an obese state. The T allele also appears to be
an important determinant of CVD risk; however, this may
correlatedirectlywith thetendencyofTallelecarrierstohave
increased adiponectin levels, as demonstrated in one study
in which the diabetic participants with the TT genotype had
lower risk of CVD, while those without CVD had higher
adiponectin levels [71]. Several other studies identiﬁed the
T allele as a determinant of cardiovascular risk [65, 72].
Overall, the magnitude of change in adiponectin levels
varies considerably between studies. This is not surprising,
since the studies examine populations that are very diﬀerent
in ethnicity, age, and health condition. However, it is worth
noting that several studies show quite substantial changes
in adiponectin levels and therefore provide convincing
evidence that seemingly minute variations in the genetic
code can produce large changes in adipokine levels, and thus
signiﬁcantly aﬀect health status.
3.2. AdipoQ Nutrient-Gene Interactions. Subtle genetic vari-
ations can have a large impact on important obesity-
related disease determinants, as demonstrated by many of
studies discussed above. Individuals with SNPs in genes
such as AdipoQ can be subject to greater sensitivity to
dietary factors, due to the critical role adiponectin plays
in maintaining metabolic balance. Several recent studies
have investigated the nutrient-gene interactions that take
place between dietary factors and AdipoQ SNPs. P´ erez-
Mart´ ınez et al. [83] investigated the inﬂuence of dietary
fat on insulin resistance in C allele carriers of the −11377
G > C SNP in Caucasian men and women. Only men
who were homozygous for the C allele had signiﬁcantly
lower IR after consuming monounsaturated (MUFA-) and
carbohydrate-rich diets than after consuming an SFA-rich
diet. In a population of European Caucasian ancestry with
MUFA intake above the median, lower BMI and decreased
obesity risk were observed in carriers of the −11391 A allele
[84]. The +45, +276, and −11377 SNPs were examined
in 363 subjects with impaired fasting glucose or newly
diagnosed type 2 diabetes following a dietary intervention
(replacement of cooked reﬁned rice with whole grains and
an increase in vegetable intake) and regular walking for
12 weeks without any medication. Fasting glucose levels
declined in all genotype groups of the +45 T > G SNP, and
TT homozygotes had increased adiponectin levels and lower
HOMA-IR indexes [85]. In another study, obese Japanese
women with the +276 SNP were placed on a low-calorie diet
for 8 weeks. At the study conclusion, those with a GT or
TT genotype had a greater decrease in waist circumference,
and those with the TT genotype in the +45 SNP had lower
plasmatriglycerides.Inthesamepopulation,theparticipants
with CG and GG genotypes at SNP −11377 enjoyed a
greaterdecrease in systolic bloodpressure and fasting plasma
glucose than those with CC [86]. Each of these studies
used appropriate statistical testing to determine signiﬁcant
interactionsbetweenthegenepolymorphismsandmetabolic
parameters. These ﬁndings correspond with the trends in
metabolic disease discussed in the previous section.
4.Leptin
Leptin regulates body weight and energy expenditure, and
plays important roles in the modulation of glucose and lipid
metabolism, angiogenesis, immunity, and blood pressure
homeostasis. Leptin is also a critical signalling molecule
in the hypothalamus, where it inﬂuences appetite and
satiety. The circulating levels of leptin correlate directly
with adipocyte number and size [87], thus, leptin levels
are elevated in obesity and are thought to exacerbate many
of the negative eﬀects of weight gain, such as contributing
to the local inﬂammatory response [88] and creating a
positive feedback loop for feeding behaviour through leptin
resistance [89]. More details on the many roles of leptin in
metabolic disease can be found in recent reviews [90–92].
The study of leptin began when mice homozygous
for single-gene mutations in the leptin gene (ob/ob)a n d
the leptin receptor gene (db/db) were identiﬁed [93]. The
absence of leptin or its receptor leads to uncontrolled
eating, and mice with either defect become massively obese.
Treatment of ob/ob mice with leptin injections brings about
a reduction in body weight to that of a normal mouse.
For this reason, leptin was once believed to be the solution
to the Western world’s epidemic of obesity. Unfortunately,
it was soon determined that such monogenic mutations
occur very rarely in humans. In fact, severe obesity due to
a single mutation in the leptin gene has been observed in
only 12 human cases in the entire world [94]. It is now clear
that multiple genes and gene variants are involved in the
development of human obesity. SNPs in the human leptin
gene (Lep) and the leptin receptor gene (LepR)c a nh a v e
a profound impact on body weight, insulin resistance and
othermetabolicdisease parameters. Theliteraturedescribing
the eﬀects of these SNPs is summarized in Table 2.
4.1. Leptin and Leptin Receptor Gene Variants: Risk for
Obesity-Related Metabolic Disease. The Lep gene is located
onchromosome7q31andencompassesapproximately20kb.
It contains 3 exons, the ﬁrst of which is noncoding.
Its sequence is highly conserved and contains very little
reported variation. Only one leptin SNP, +19 G > A, has
been investigated in detail for its eﬀects on obesity-related
metabolic disease. A recent study found that the A allele
was signiﬁcantly associated with lower body weight, lower
BMI, lower circulating leptin levels, and consequently, a
lower risk for obesity in Caucasian and African-American
women [100]. Another reported that the presence of the
A allele was linked to higher leptin levels and lower BMI
in obese Caucasian females compared to GG homozygotes,
suggesting that carriers of this allele may experience better
sensitivitytosatietysignalsviatheleptinprotein[99].Several
other publications failed to ﬁnd any signiﬁcant associations
between this SNPand BMI orblood lipid levels[96–98]. The
Lep +19 A > G variant lies within the ﬁrst untranslated exon
ofthegene,anditisnotknownhow suchan alterationmight
modify protein function. However, it is has been suggested
that the Lep +19 A > G SNP is in disequilibrium with
promoter region variation that may have an eﬀect on gene
transcription [100].Journal of Obesity 9
Table 2: SNPs in the Leptin (Lep) and Leptin Receptor (LepR) Genes.
SNP ID Amino acid
change
Nucleotide
change Parameter association Population Leptin level
(% change)
P value Reference
Leptin (Lep)
rs4731427
SNP associated with weight
and waistcircumference in
African Americans
Young adults
(Caucasians,
African
Americans)
[95]
+19G > A
No associationwith BMI,
WHR, fasting glucose &
insulin, lipids and leptin
levels
[96]
No associationwith waist
girth, plasma triglycerides,
HDL-cholesterol, glucose
and systolic, and diastolic
blood pressure
French
Caucasian
[97]
No associationwith
waist-to-hip ratio, fasting
leptin, total cholesterol,
high-density lipoproteins,
triglycerides
Italian
Caucasian
(obese/non-
obese)
[98]
No genotype associated
with BMI, but A allele
associated with higher
leptin levels in obese
patients
French
Caucasian
(obese/non-
obese)
18.93 .001 [99]
A allele in females
associated with lower body
weight, BMI and plasma
leptin levels, lower risk of
obesity
African
Americans and
Caucasians
6.68 .01 [100]
rs17151919
SNP associated with weight
and waistcircumference in
African Americans and
weight in Caucasians,waist
circumference in Caucasian
women
Young adults
(Caucasians,
African
Americans)
[95]
rs28954369
SNP associated with
weight, waist circumference
in African Americans and
weight in Caucasians,waist
circumference in Caucasian
women
Young adults
(Caucasians,
African
Americans)
[95]
rs2167270
SNP associated with weight
in Caucasians,waist
circumference in Caucasian
women
Young adults
(Caucasians,
African
Americans)
[95]
rs7799039 G > A A allele signiﬁcantly
associated with BMI Caucasians [101]
−2548 G > A
G allele associated with
overweight, and with lower
leptin concentrations in
men
17.46 .05 [102]
A allele not associated with
obesity
Spanish
Mediterranean
[103]10 Journal of Obesity
Table 2: Continued.
SNP ID Amino acid
change
Nucleotide
change Parameter association Population Leptin level
(% change) P value Reference
Leptin Receptor (LepR)
rs1137101 Gln223Arg A > G
G allele associated with
BMI, WHR, leptin levels,
and insulin levels
Asian Indians
(diabetic/
nondiabetic)
.001 [104]
G allele associated with
higher BMI, fat mass, and
serum leptin levels
Caucasian
women (post-
menopausal)
31.15 .0001 [105]
GG genotype associated
with BMI in nonsmokers
Braziliansof
European
descent
(Caucasian)
[106]
G allele associated with
increased rates of obesity,
higher BMI and % fat mass
Greek [107]
GG genotype had larger
subcutaneous abdominal
adipocyte size than AA,
however, no diﬀerence in
overall adiposity
Pima Indians [108]
G allele associated with
insulin resistance Caucasians [109]
GG phenotype associated
with lean phenotype
Spanish
Mediterranean [103]
GG and AG genotypes
associated with increased
risk of familial
hypercholesterolemia, but
not obesity, insulin
resistance or other lipid
parameters
Dutch [110]
G allele associated with
increased rate of obesity
Brazilians
(obese/non-
obese)
[111]
AA genotype was
associated with increased
total abdominal fat
Belgian
Caucasian
women
(overweight
and obese)
[112]
No associationwith BMI,
fasting insulin, HOMA-IR,
serum leptin, or soluble
leptin receptor levels
Japanese [113]
G allele associated with
increased adiposity
Danish post-
menopausal
women
[114]
GG genotype had lower
blood pressure compared
to AA
Swedish men
(hypertensive/
normotensive)
[115]
G allele associated with
CRC risk
Czech (CRC
patients) [46]
G allele associated with
higher fat mass and BMI [116]
A allele associated with
higher insulin, leptin levels,
and body fat
Mexican
adolescents 62.02 .001 [117]
No associationwith BMI,
WHR, fasting glucose &
insulin, lipids and leptin
levels
[96]Journal of Obesity 11
Table 2: Continued.
SNP ID Amino acid
change
Nucleotide
change Parameter association Population Leptin level
(% change)
P value Reference
AA genotype had greater
risk of developing T2DM
Finnish
(impaired
glucose
tolerance)
[118]
G allele associated with
BMI, change in BMI over
time
[119]
Ser(T)343-
Ser(C) T > C
T allele associated with
overweight and fat mass in
women; C allele carriers
more responsive to weight
loss on a low calorie diet
[120]
+70 T > C C allele associated with fat
mass in women
[120]
Lys656Asn G>C G allele associated with
higher lean and fat mass Caucasians [121]
No associationwith
obesity, BMI, or % fat mass Greek [107]
C allele associated with
increased hip
circumference, total
abdominal fat, and
subcutaneous fat
Belgian
Caucasian
women
(overweight
and obese)
[112]
C allele associated with
higher fasting glucose and
fasting insulin in
postmenopausal women
Belgian
Caucasian
women
(overweight
and obese)
[122]
No associationwith blood
pressure or BMI
Swedish men
(hypertensive/
normotensive)
[115]
No associationwith blood
pressure, serum glucose,
insulin, or leptin levels
Mexican
adolescents
[117]
Arg109Lys +5193 G > A
No associationwith BMI,
WHR, fasting glucose &
insulin, lipids and leptin
levels
[96]
AA genotype wasassociated
with higher leptin levels in
postmenopausal women
Belgian
Caucasian
women
(overweight
and obese)
14.99 .02 [112]
A allele positively
associated with BMI Korean [123]
No associationwith BMI,
fasting insulin, HOMA-IR,
serum leptin, or soluble
leptin receptor levels
Japanese [113]
No associationwith
obesity, BMI, or % fat mass Greek [107]
A allele associated with
fasting insulin in
postmenopausal women
Belgian
Caucasian
women
(overweight
and obese)
[122]12 Journal of Obesity
Table 2: Continued.
SNP ID Amino acid
change
Nucleotide
change Parameter association Population Leptin level
(% change)
P value Reference
AA genotype had greater
risk of developing T2DM
Finnish
(impaired
glucose
tolerance)
[118]
GG genotype had lower
blood pressure and lower
BMI compared to AA
Swedish men
(hypertensive/
normotensive)
[115]
rs1045895 SNP associated with change
in BMI over time
[119]
The LepR gene is found on chromosome 1p31, spans
about 100kb, and contains 20 exons. Numerous analyses
of LepR SNPs have been published over the last decade,
as the role of these genetic variants as determinants of
adiposity and related conditions has become clear. The SNP
Gln223Arg A > G has been studied extensively in a wide
range of populations. The G allele is primarily associated
with increased adiposity, BMIand percent fat mass, as well as
higher circulating insulin and leptin levels. Larger adipocyte
size has also been observed in individuals with the GG
genotype. A couple of studies revealed varying results, with
theG allele linkedtoa lean phenotype[103] and lowerblood
pressure [115], or no association whatsoever with weight-
related parameters [96, 113]. Conversely, the A allele has
also been found to be associated with total abdominal fat
mass, increased insulin and leptin levels, and higher risk of
developing T2DM [117].
The Lys656Asn G > C SNPwas analyzed in several diﬀer-
ent populations, but no consistent trends were identiﬁed—
bothalleles are associated with increased fat mass in diﬀerent
ethnic groups [112, 121], whereas the C allele has also been
linked to increased fasting glucose and fasting insulin [122].
Two studies also reported no association between this SNP
and blood pressure, BMI, leptin levels, insulin and serum
glucose [115, 117].
The A allele of the Arg109Lys G > A SNP is associated
with increased T2DM risk [118], higher leptin levels [112],
and higher BMI [123]. Several studies reported no associa-
tionbetweenthisSNPandobesity-relateddiseaseparameters
[96, 107, 113], while one study found the GG, but not AA,
genotypetobelinkedtolowerbloodpressureandBMI[115].
Functional data on these polymorphisms is scarce, and
the mechanisms by which the genetic variation inﬂuences
metabolism and obesity are largely speculative at this point
in time. The increased fat mass and leptin levels in many
of the LepR S N Pc a r r i e r sp o i n t st o w a r dap o s s i b l ec h a n g e
in binding aﬃnity for the leptin receptor. The receptor
functions in a dimeric form both in serum and at the cell
surface. The genetic variations in the coding gene for the
receptor may alter the ability of subunits to form dimers,
leading to the phenotypic diﬀerences observed. Quinton et
al. [105] measured the leptin-binding activity of the soluble
leptin receptor in study participants who were carriers of
the Gln223Arg SNP and found signiﬁcantly higher activity
in individuals homozygous for the G allele than for the A
allele. These authors suggest the change in binding aﬃnity
might also result in an evolutionarily signiﬁcant tendency to
higherfat mass, contributing totheﬁxation ofthese allelesin
human populations.
4.2. Gene-Nutrient Interactions with Lep and LepR. Most of
the literature on gene-nutrient interactions involving leptin
or the leptin receptor focuses on fetal nutrition and leptin
levels in breast-feeding mothers. Recent evidence suggests
that early prenatal and postnatal nutrition has an impact on
susceptibility to chronic disease later in life. Leptin in breast
milk has been identiﬁed as a key protective factor against
several metabolic and physiological changes at an older age,
such as obesity and related medical complications [124].
Several recent reviews on this topic are available [125, 126].
There is scant research on the interactions of leptin
or leptin receptor gene SNPs with dietary factors. One
study analyzed the eﬀects of leptin receptor polymorphisms
and PUFA consumption in relation to insulin resistance
and metabolic syndrome [127]. The ﬁndings revealed that
participants in the lowest median of plasma (n-3) PUFA
and LCPUFA with the GG genotype of the rs3790433
SNP were at higher risk for hyperinsulinemia and insulin
resistance, whereas in individuals with the same genotype
but high plasma (n-3) PUFA and LCPUFA the risk of
developing hyperinsulinemia and insulin resistance was
eﬀectively eliminated. Moreover, a high-plasma (n-6) PUFA
proﬁle accentuated the risk of these same conditions in
GG homozygotes. The study concluded that homozygous
carriers of this SNP may be predisposed to metabolic
syndrome compared with the A allele carriers, especially if
theplasmafattyacidproﬁlewasunfavourable.Anotherstudy
assessed the inﬂuence of the LepR Lys656Asn polymorphism
on the leptin response secondary to a low fat or low
carbohydrate diet in obese people [128]. Leptin levels were
signiﬁcantly lower in the Lys656/Lys656 cohort on a low fat
diet than on a low carbohydrate diet. The Lys656/Lys656
group also enjoyed a decrease in several obesity-related
disease parameters (BMI, weight, fat mass, blood pressure,
total cholesterol, triglycerides, blood insulin, and glucose)
on a low fat diet, while signiﬁcant changes in only BMI,
weight and fat mass were observed in Asn656 carriers on
the same diet. These studies indicate that polymorphismsJournal of Obesity 13
in the leptin receptor genes can play an inﬂuential role in
the body’s physiological response to diet. There is a need for
more research in this important area.
5.ConcludingRemarks
In summary, the current literature demonstrates that SNPs
in the genes for adiponectin, leptin, and the leptin receptor
can to a great degree inﬂuence the carriers’ susceptibility
to obesity and related complications. While epidemiological
studies have reported associations between adipokine levels
and metabolic disease parameters, the evidence compiled
here provides a compelling argument for the causality of
adipokine levels in disease. In many of the studies cited here,
changes in adipokine levels were observed in individuals
withgenepolymorphisms, andthus,thechange inadipokine
levels precedes the occurrence of pathological conditions.
Varied downstream eﬀects on parameters of health are
to be expected, since the adipokines examined here play
diverse roles in many organ systems, as recently reviewed by
DeClercq et al. [129]. The genetic variants included in this
review by no means constitute an exhaustive list, and further
investigation of adipokine SNPs and their impact on human
health is warranted. Furthermore, population diﬀerences
are also a factor in the strength of genetic determinants
of disease. The gene-nutrient interaction studies discussed
emphasize the role of diet in the modiﬁcation of risk for
developing metabolic disease. Future research in this ﬁeld is
needed to conﬁrm and expand the ﬁndings presented here.
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